{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-263831","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2026-06-09T20:28:58+00:00","discovered_at":"2026-06-09T20:30:04.362076+00:00","generated_at":"2026-06-09T20:30:23.737696+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.","bullets":["Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.","Complete DR3 occupancy at all doses ≥0.1 mg/kg; PK modeling suggests >3 months blockade at doses ≥1 mg/kg.","No serious TEAEs; all TRAEs Grade 1; no DR3 agonism or lymphocyte proliferation observed.","RECEPTIVE-CD1 Phase 2b in Crohn's expected to start Q3 2026; primary endpoint endoscopic response at Week 12.","Warrant exercise for ~50.6M shares (96% of Aug 2025 placement) yields ~$54.9M gross; cash runway into 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-263831","json":"https://secwatch.observer/filing/0001193125-26-263831.json","markdown":"https://secwatch.observer/filing/0001193125-26-263831.md","text":"https://secwatch.observer/filing/0001193125-26-263831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/0001193125-26-263831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/d120796d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:30:23.737696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}